Bionano Genomics Cuts Costs 47%, Guides 2026 Revenue of $30–33 Million
Bionano Genomics reported Q4 revenue of $8.0 million, down 3% year-over-year, and full-year 2025 revenue of $28.5 million, down 7%, while non-GAAP gross margin rose to 47% and non-GAAP operating expenses plunged 47%. The company ended 2025 with $29.6 million cash and set 2026 revenue guidance of $30–33 million.
1. Q4 2025 Financial Results
Bionano Genomics posted Q4 revenue of $8.0 million, a 3% decrease from Q4 2024, driven by a 1% drop in consumables and software and $2.7 million in instrument sales; flowcell unit sales fell 6% to 7,554 and gross margin rose to 43%, while operating expenses fell 22% to $11.9 million (non-GAAP $9.7 million).
2. Full-Year 2025 Highlights
For the full year, revenue totaled $28.5 million, down 7% year-over-year, with consumables and software revenue up 7% but instrument revenue down to $6.4 million; non-GAAP gross margin expanded to 47% and operating expenses declined 47% to $36.6 million, ending the year with $29.6 million in cash and equivalents.
3. Operational and Clinical Progress
The company secured a 47% increase in Medicare payment for its Category I CPT code for OGM in hematologic malignancies, showcased advances at its symposium with nearly 40 presentations, and reached 136 peer-reviewed publications in Q4, as it expands international OGM networks and fosters clinical adoption.
4. 2026 Revenue Outlook
Bionano expects Q1 2026 revenue between $6.5 million and $6.7 million and full-year 2026 revenue of $30 million to $33 million, reflecting confidence in continued utilization growth and margin expansion.